rs111887056

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 1P and 20B. PP2BP4_StrongBP6_Very_StrongBA1

The NM_000153.4(GALC):​c.61G>C​(p.Ala21Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.139 in 1,586,544 control chromosomes in the GnomAD database, including 16,679 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Uncertain significance in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A21V) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.11 ( 1112 hom., cov: 33)
Exomes 𝑓: 0.14 ( 15567 hom. )

Consequence

GALC
NM_000153.4 missense

Scores

8
10

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:12

Conservation

PhyloP100: 0.562

Publications

27 publications found
Variant links:
Genes affected
GALC (HGNC:4115): (galactosylceramidase) This gene encodes a lysosomal protein which hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Mutations in this gene have been associated with Krabbe disease, also known as globoid cell leukodystrophy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
GALC Gene-Disease associations (from GenCC):
  • Krabbe disease
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Myriad Women’s Health, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), PanelApp Australia, ClinGen, Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 94 curated pathogenic missense variants (we use a threshold of 10). The gene has 16 curated benign missense variants. Gene score misZ: 0.18582 (below the threshold of 3.09). Trascript score misZ: -0.28853 (below the threshold of 3.09). GenCC associations: The gene is linked to Krabbe disease.
BP4
Computational evidence support a benign effect (MetaRNN=0.0018750429).
BP6
Variant 14-87993104-C-G is Benign according to our data. Variant chr14-87993104-C-G is described in ClinVar as Benign. ClinVar VariationId is 92508.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.152 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GALCNM_000153.4 linkc.61G>C p.Ala21Pro missense_variant Exon 1 of 17 ENST00000261304.7 NP_000144.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GALCENST00000261304.7 linkc.61G>C p.Ala21Pro missense_variant Exon 1 of 17 1 NM_000153.4 ENSP00000261304.2

Frequencies

GnomAD3 genomes
AF:
0.112
AC:
17026
AN:
152156
Hom.:
1109
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0395
Gnomad AMI
AF:
0.133
Gnomad AMR
AF:
0.130
Gnomad ASJ
AF:
0.119
Gnomad EAS
AF:
0.00231
Gnomad SAS
AF:
0.0947
Gnomad FIN
AF:
0.154
Gnomad MID
AF:
0.134
Gnomad NFE
AF:
0.154
Gnomad OTH
AF:
0.109
GnomAD2 exomes
AF:
0.115
AC:
21968
AN:
190848
AF XY:
0.114
show subpopulations
Gnomad AFR exome
AF:
0.0329
Gnomad AMR exome
AF:
0.135
Gnomad ASJ exome
AF:
0.112
Gnomad EAS exome
AF:
0.000725
Gnomad FIN exome
AF:
0.148
Gnomad NFE exome
AF:
0.139
Gnomad OTH exome
AF:
0.121
GnomAD4 exome
AF:
0.142
AC:
203924
AN:
1434276
Hom.:
15567
Cov.:
33
AF XY:
0.141
AC XY:
100074
AN XY:
710896
show subpopulations
African (AFR)
AF:
0.0341
AC:
1127
AN:
33054
American (AMR)
AF:
0.139
AC:
5735
AN:
41128
Ashkenazi Jewish (ASJ)
AF:
0.117
AC:
3008
AN:
25622
East Asian (EAS)
AF:
0.00124
AC:
48
AN:
38578
South Asian (SAS)
AF:
0.100
AC:
8314
AN:
82906
European-Finnish (FIN)
AF:
0.158
AC:
7762
AN:
49084
Middle Eastern (MID)
AF:
0.158
AC:
889
AN:
5614
European-Non Finnish (NFE)
AF:
0.154
AC:
169279
AN:
1099038
Other (OTH)
AF:
0.131
AC:
7762
AN:
59252
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
9449
18898
28348
37797
47246
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
5930
11860
17790
23720
29650
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.112
AC:
17035
AN:
152268
Hom.:
1112
Cov.:
33
AF XY:
0.112
AC XY:
8361
AN XY:
74464
show subpopulations
African (AFR)
AF:
0.0396
AC:
1645
AN:
41566
American (AMR)
AF:
0.130
AC:
1994
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
0.119
AC:
414
AN:
3470
East Asian (EAS)
AF:
0.00232
AC:
12
AN:
5174
South Asian (SAS)
AF:
0.0946
AC:
457
AN:
4830
European-Finnish (FIN)
AF:
0.154
AC:
1638
AN:
10618
Middle Eastern (MID)
AF:
0.130
AC:
38
AN:
292
European-Non Finnish (NFE)
AF:
0.154
AC:
10488
AN:
67998
Other (OTH)
AF:
0.108
AC:
228
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
830
1660
2489
3319
4149
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
184
368
552
736
920
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.140
Hom.:
554
Bravo
AF:
0.106
TwinsUK
AF:
0.139
AC:
517
ALSPAC
AF:
0.146
AC:
564
ESP6500AA
AF:
0.0366
AC:
109
ESP6500EA
AF:
0.115
AC:
777
ExAC
AF:
0.0887
AC:
10059
Asia WGS
AF:
0.0530
AC:
185
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Galactosylceramide beta-galactosidase deficiency Benign:5
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 21, 2019
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Jul 01, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:4
Jan 03, 2013
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
Oct 26, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Benign
-0.24
T
BayesDel_noAF
Uncertain
0.030
CADD
Benign
21
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.52
D;.
Eigen
Uncertain
0.33
Eigen_PC
Uncertain
0.23
FATHMM_MKL
Benign
0.61
D
LIST_S2
Benign
0.79
T;T
MetaRNN
Benign
0.0019
T;T
MetaSVM
Benign
-0.95
T
MutationAssessor
Uncertain
2.4
M;M
PhyloP100
0.56
PrimateAI
Uncertain
0.74
T
PROVEAN
Benign
0.020
N;N
REVEL
Uncertain
0.51
Sift
Benign
0.072
T;D
Sift4G
Benign
0.13
T;T
Polyphen
1.0
D;.
Vest4
0.17
MPC
0.66
ClinPred
0.033
T
GERP RS
3.2
PromoterAI
0.025
Neutral
Varity_R
0.14
gMVP
0.74
Mutation Taster
=96/4
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs111887056; hg19: chr14-88459448; COSMIC: COSV54324700; COSMIC: COSV54324700; API